Reconsolidation Blockade of Intrusive Trauma- and Cocaine-related Memories (NCT05902819) | Clinical Trial Compass
CompletedNot Applicable
Reconsolidation Blockade of Intrusive Trauma- and Cocaine-related Memories
Switzerland138 participantsStarted 2023-05-10
Plain-language summary
An investigation of the effect of matrix-metalloproteinase-(MMP)-9 inhibition with minocycline on the reconsolidation of trauma- or cocaine-related memories
Who can participate
Age range18 Years – 60 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
General Inclusion Criteria:
* Ability to read, understand and provide written informed consent
* Age between 18 and 60 years
* To be sufficiently fluent in German
Inclusion Criteria for the PTSD group:
\- Current diagnosis of full PTSD according to the 5th version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), of subthreshold PTSD, as in meeting two to three of the DSM-5 criteria B-E, or of complex PTSD
Inclusion Criteria for the CUD group:
* Current diagnosis of mild, moderate, or severe CUD according to DSM-5
* Regular cocaine use in the last 12 months and at least one consumption event in the last 6 months
Inclusion Criteria for the Clinical Controls (PTSD+CUD group):
* Current diagnosis of full PTSD according to the 5th version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), of subthreshold PTSD, as in meeting two to three of the DSM-5 criteria B-E, or of complex PTSD
* Current diagnosis of mild, moderate, or severe CUD according to DSM-5
* Regular cocaine use in the last 12 months and at least one consumption event in the last 6 months
Exclusion Criteria for the HC, PTSD, CUD, and PTSD+CUD groups:
* Women who are pregnant or breast feeding or intending to become pregnant during the course of the study or within 3 months after
* Other clinically significant concomitant disease states, e.g., renal failure (i.e., estimated glomerular filtration rate (eGFR; CKD-EPI) lower than 60 ml/min/1.73 m2), hepatic dysfunction (i.e.…
What they're measuring
1
Changes in intrusive memories frequency and features
Timeframe: Changes from baseline intrusive memories frequency and features after both 9 to 39 days (follow-up 1) and approx. 3.5 months (follow-up 2)
2
Change over time in self-reported intrusive memories frequency, arousal and distress
Timeframe: EMA will be conducted for an average of 12 to 42 days (through study participation from baseline to 3 days after follow-up 1).